<DOC>
	<DOCNO>NCT00871598</DOCNO>
	<brief_summary>Patients plaque psoriasis enrol . They dose repeat intravenous dos BTT-1023 placebo . During trial , safety treatment pharmacokinetics BTT-1023 assess . The patient allocation treatment group occur random , actual treatment reveal investigator patient trial .</brief_summary>
	<brief_title>BTT1023 Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Plaque psoriasis affect least 8 % body surface area score 8 high psoriasis area severity index Seropositive infection human immunodeficiency virus , hepatitis B virus , hepatitis C virus ; Tuberculosis ; Acute systemic infection ; Treatment monoclonal antibody therapy within 12 week prior study entry ; An absolute indication know effective treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>plaque psoriasis</keyword>
	<keyword>BTT1023</keyword>
	<keyword>safety</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>